Market Research Logo

Vital Signs - The Analyst's Perspective - June 2015 Issue

Vital Signs - The Analyst's Perspective - June 2015 Issue

Affymetrix acquired all the assets of Eureka Genomics, including its high throughput crop and animal genotyping technology, for $15 million. Eureka’s assays use next-generation sequencing (NGS), a rapidly growing technology utilized in various applications. As part of the acquisition, Affymetrix has also signed a multi-year contract to offer Eureka’s technologies to Zoetis for use in animal genetics. Zoetis is a subsidiary of Pfizer and is the largest producer of medicine and vaccinations for pets and livestock

The Analyst’s Perspective by Divyaa Ravishankar, Senior Industry Analyst, Life Sciences, North America

Molecular testing is a rapidly growing area in healthcare. The fields of application are now extending beyond life sciences and clinical diagnostics to other areas. Next-generation sequencing technologies are rapidly being employed in animal testing for testing pathogens. This is an emerging segment that requires a lot of trait management and traceability. Gene testing for animal health and cattle management has been relatively expensive, and technologies to facilitate broader genotyping of low-density traits, such as parentage, have been limited.

Eureka Genomics is a developer of cost-effective high, medium, and low assays that use NGS technology for signal read out. These assays can enable the detection of several genetic markers that have high prevalence in crop and animal genomic testing. Eureka also provides NGS and genotyping services to government agencies, universities, research centers, and agriculture companies. Its assays can be applied to detection of copy number variation (CNV), methylation, and single nucleotide polymorphisms (SNPs). The information is compatible with any DNA or RNA from any organism, despite the incompleteness of genome information. This makes the technology very unique and powerful, answering several questions by combining discriminatory power of hybridization and ligation. Furthermore, Eureka’s assays are NGS instrument agnostic and can be easily adapted to any modifications made in the instruments, such as upgrading, data generation, or even change of instrument.

Affymetrix Acquires Eureka Genomics for $15 Million
OPKO Health, Inc. Acquires Bio-Reference Laboratories, Inc. for $1.47 Billion in Stock
Target Signs the Dotted Line Facilitating CVS Health to Acquire its In-store
Pharmacies and Clinics
Thermo Fisher Scientific Acquires Alfa Aesar, Further Consolidating
Life Science Chemicals Market

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report